Jazz Pharmaceuticals plcJAZZNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 26.70% |
| Q2 2025 | 5.16% |
| Q1 2025 | -24.88% |
| Q4 2024 | 20.30% |
| Q3 2024 | -9.43% |
| Q2 2024 | -0.95% |
| Q1 2024 | 2.88% |
| Q4 2023 | -7.59% |
| Q3 2023 | 12.03% |
| Q2 2023 | 10.47% |
| Q1 2023 | 9.77% |
| Q4 2022 | 15.91% |
| Q3 2022 | 7.06% |
| Q2 2022 | 6.97% |
| Q1 2022 | -16.38% |
| Q4 2021 | 10.22% |
| Q3 2021 | 6.29% |
| Q2 2021 | 73.29% |
| Q1 2021 | -16.50% |
| Q4 2020 | 16.60% |
| Q3 2020 | -0.35% |
| Q2 2020 | -8.34% |
| Q1 2020 | -11.58% |
| Q4 2019 | 21.95% |
| Q3 2019 | 28.01% |
| Q2 2019 | 3.79% |
| Q1 2019 | 6.09% |
| Q4 2018 | 10.74% |
| Q3 2018 | -8.86% |
| Q2 2018 | -10.43% |
| Q1 2018 | -5.04% |
| Q4 2017 | 39.34% |
| Q3 2017 | 17.94% |
| Q2 2017 | -10.62% |
| Q1 2017 | 1.74% |
| Q4 2016 | -7.61% |
| Q3 2016 | 22.27% |
| Q2 2016 | 25.08% |
| Q1 2016 | 6.10% |
| Q4 2015 | -42.00% |